Galderma stock: Mexico grants first global jawline approval
Published on 11/14/2026 at 12:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMexico approval expands Restylane reach
- Mexico approved Restylane Shaype for temporary chin augmentation and jawline definition.
- The approval marks the product's first global authorization for jawline use, with launch expected in the first half of 2027.
On Friday, November 13, Galderma announced that Mexico had approved Restylane Shaype for temporary chin augmentation and improved jawline definition. The company described the decision as the product's first approval worldwide for jawline use. The announcement was published in a Galderma press release.
A new indication for Restylane
The approval expands Restylane Shaype's use in Mexico beyond chin augmentation to include jawline definition. Galderma expects to launch the product in the first half of 2027, subject to the rollout in the market.
Restylane Shaype is a hyaluronic acid injectable designed as a firmer gel for structural enhancement of the lower face. Galderma said the product is already approved for chin use in several markets, including Europe, Brazil, Canada and Thailand.
Clinical results support the rollout
Galderma cited a 12-month chin study in which 83 percent of participants showed improved structure and definition after three months, compared with 66 percent after 12 months. The company also said jawline improvements remained in place for up to two years in clinical data.
Galderma stock traded at 207.10 euros on Lang & Schwarz at 12:09 CET on Saturday, November 14.
Galderma company facts
- Company: Galderma Group AG
- ISIN: CH1335392721
- Stock symbol: GALD
- Home exchange: SIX Swiss Exchange
- Latest quoted price: 207.10 euros on Lang & Schwarz, Saturday, November 14, 2026, at 12:09 CET
The broader Swiss market context is covered in Current market reports.
